 DEVON, Pa., March 10, 2021 GLOBE NEWSWIRE -- Zynerba Pharmaceuticals, Inc. Nasdaq: ZYNE, the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the fourth quarter and full year ended December 31, 2020, and provided an overview of recent operational highlights and a pipeline update. 